Mainz Biomed shares surge 17.51% premarket after securing $6M financing and pivoting to U.S. pancreatic cancer screening with Lazar as Chairman.

Mainz Biomed surged 17.51% in premarket trading following the announcement of a $6.0 million private placement with investor David Lazar, who was appointed Chairman. The funding, split into two $3.0 million tranches, will support the company’s strategic pivot to its U.S. pancreatic cancer detection program, asset sales for its colorectal screening business, and the wind-down of its German subsidiary. The transaction provides liquidity to address liabilities, stabilize operations, and pursue growth opportunities, aligning with investor sentiment favoring the company’s refocused strategy. The move signals reduced operational complexity and enhanced financial flexibility, directly correlating with the sharp premarket rally.